[
  {
    "objectID": "cv.html",
    "href": "cv.html",
    "title": "Portfolio",
    "section": "",
    "text": "Source: The Pharmaceutical Journal"
  },
  {
    "objectID": "cv.html#quantitative-medicine",
    "href": "cv.html#quantitative-medicine",
    "title": "Portfolio",
    "section": "Quantitative Medicine",
    "text": "Quantitative Medicine\n\nPharmacometrics\n\nModel-informed drug discovery and development\n\nPreclinical, translational and population PK/PD modelling\n\nHuman dose prediction for clinical translation\n\nDose optimisation for clinical therapies\n\nSmall molecules and biologics"
  },
  {
    "objectID": "cv.html#drug-delivery",
    "href": "cv.html#drug-delivery",
    "title": "Portfolio",
    "section": "Drug Delivery",
    "text": "Drug Delivery\n\nInhaled formulations\n\nPulmonary drug delivery\n\nPhysicochemical characterisation\n\nSpray-drying and particle engineering\n\nParticle size and aerosolisation\n\nBiologics delivery via inhalation"
  },
  {
    "objectID": "cv.html#oncology-haematology",
    "href": "cv.html#oncology-haematology",
    "title": "Portfolio",
    "section": "Oncology / Haematology",
    "text": "Oncology / Haematology\nBlood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are characterised by dysfunctional immune system and leukaemic stem cell proliferation.\nIn oncology, thrombocytopenia is a commonly reported dose-limiting toxicity. In one project, I contributed to understanding of intertwining effects of drug and disease on platelet dynamics in haematological malignancies to support dosing decisions in cancer patients."
  },
  {
    "objectID": "cv.html#neuroscience",
    "href": "cv.html#neuroscience",
    "title": "Portfolio",
    "section": "Neuroscience",
    "text": "Neuroscience\nMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In MS, patients experience a wide range of life-limiting symptoms, ranging from problems with vision, movement and sensation to fatigue, pain and issues with memory and thinking.\nIn neuroscience, I support the clinical development and registration of new generation disease-modifying therapies for MS and other neurological conditions, for the development of small-molecules and biologics.\nIn one project, I supported evaluating the use of continuous-time Markov models as a means for fitting disease progression models in MS using the NO.MS dataset, which is the largest clinical trial dataset for MS complied by Novartis and Oxford, containing data from approximately 35,000 patients spanning all MS phenotypes and including up to 15 years of follow-up."
  },
  {
    "objectID": "cv.html#nanobody",
    "href": "cv.html#nanobody",
    "title": "Portfolio",
    "section": "Nanobody®",
    "text": "Nanobody®\nNanobody molecules belong to a new class of biologics that are derived from heavy-chain-only peptides and are around a tenth the size of conventional antibodies.\nIn Sanofi, as a clinical pharmacometrician in development project teams, I contributed to the population PK/PD modelling and simulation activities for the development of both small molecules and biologics in clinical studies (FIH to Ph3), including first-in-human evaluation, proof-of-concept study design, international submission, labelling extension, paediatrics extrapolation and alternative dosing regimen exploration.\nIn one project, I was involved in preparing the submission package to PMDA in Japan for extending the use of caplacizumab to paediatric patients in the Japanese population. Due to the indication being a rare disease, dose extrapolation using a modelling approach, without any clinical data in paediatric patients, was used to support this submission."
  },
  {
    "objectID": "cv.html#global-health",
    "href": "cv.html#global-health",
    "title": "Portfolio",
    "section": "Global health",
    "text": "Global health\nEvery year nearly 300,000 women die due to pregnancy-related causes, with the risk of a woman in a developing country dying from a maternal-related cause during her lifetime around 23 times higher than a woman living in a developed country.\nIn GSK, as a formulation scientist and a project liaison, I successfully helped establish and secure the industrial-academic partnership between GSK and Monash, for the joint development of a novel inhaled formulation for maternal health in developing countries.\nSpecifically, as an inventor of the patent, I led the technical transfer and product translation in the development of a novel inhaled formulation for pulmonary delivery of biologics and supported its development feasibility study, which eventually resulted in a co-development and licensing agreement."
  },
  {
    "objectID": "cv.html#antimicrobials-enable",
    "href": "cv.html#antimicrobials-enable",
    "title": "Portfolio",
    "section": "Antimicrobials / ENABLE",
    "text": "Antimicrobials / ENABLE\nThe European Gram-negative Antibacterial Engine (ENABLE) is a consortium under the Innovative Medicines Initiatives (IMI) funded by the EU. It is a public-private partnership for the development of new treatments with industry partners to combat antimicrobial resistance.\nIn this consortium, I represented the pharmacometrics function from Uppsala University in cross-functional project teams to support the development of new antimicrobials for industry partners. Specifically, I contributed to the PK/PD modelling and simulation activities in industrial projects, including preclinical and translational PK and PK/PD modelling of apramycin for human dose prediction and clinical translation.\nUppsala University is home to world-leading research groups in pharmacometrics and predictive PKPD."
  },
  {
    "objectID": "cv.html#antimicrobials-jpiamr",
    "href": "cv.html#antimicrobials-jpiamr",
    "title": "Portfolio",
    "section": "Antimicrobials / JPIAMR",
    "text": "Antimicrobials / JPIAMR\nThe Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) is an EU supported initiative to combat antimicrobial resistance. I was part of the SENBIOTAR consortium funded by the programme, representing the ADME/DMPK and the drug delivery functions from Uppsala University in the global cross-functional project team.\nIn this consortium, I contributed to the screening and optimisation of novel compounds in search of candidates for early development. Specifically, I supported activities in compound characterisation and early formulation development, led and coordinated internal and external in vitro and in vivo studies for preclinical ADME/DMPK evaluation and performed preclinical PK/PD modelling to support drug candidate selection.\nUppsala University is home to UDOPP, a pharmaceutical and ADMET platform that provides support in drug discovery and early drug development projects."
  },
  {
    "objectID": "cv.html#inhalation-vaccines",
    "href": "cv.html#inhalation-vaccines",
    "title": "Portfolio",
    "section": "Inhalation & Vaccines",
    "text": "Inhalation & Vaccines\nThe unique physiology and high absorptive capacity of the lung, physiologically designed for rapid gaseous exchange, provide a potential entry route for compounds that cannot be absorbed via the gastrointestinal tract.\nIn Monash University, I was a research scientist investigating the development of dry powder formulations suitable for systemic delivery of biotherapeutics such as peptides and vaccines via inhalation.\nMonash University was recognised as number #1 in the world in the 2022 QS World University Rankings by Subject for Pharmacy and Pharmacology."
  },
  {
    "objectID": "cv.html#medication-management",
    "href": "cv.html#medication-management",
    "title": "Portfolio",
    "section": "Medication Management",
    "text": "Medication Management\nIn Australia, consultant pharmacists ensure their patients’ medications are appropriate, effective, as safe as possible and used correctly. We identify, resolve, and prevent medication-related problems that may interfere with the goals of therapy.\nThe Australian Association of Consultant Pharmacy (AACP) and, since 2023, the Pharmaceutical Society of Australia (PSA) are the major credentialing bodies responsible for the accreditation of consultant pharmacists. They promote and seek recognition for the practice of consultant pharmacy and the provision of value-added, professional services in Australia.\nFor over 10 years as a consultant pharmacist accredited by the AACP, I have served the Australian community and provided clinical services to patients and medical practitioners to promote the optimal use of medicines."
  },
  {
    "objectID": "cv.html#united-nations-volunteers",
    "href": "cv.html#united-nations-volunteers",
    "title": "Portfolio",
    "section": "United Nations Volunteers",
    "text": "United Nations Volunteers\nThe United Nations Volunteers (UNV) programme is a United Nations organisation that contributes to peace and development through volunteerism worldwide.\nIn the UNV programme, I supported research on the political economy of health issues for the United Nations Development Programme (UNDP)."
  },
  {
    "objectID": "cv.html#software",
    "href": "cv.html#software",
    "title": "Portfolio",
    "section": "Software",
    "text": "Software\n\nSou T (2025). edar: Convenient Functions for Exploratory Data Analysis. R package version 0.0.5.9000, https://soutomas.github.io/edar/dev/.\nSou T (2025). RappPBPK: Shiny Application for PBPK Simulation. R package version 0.0.0.9000, https://github.com/soutomas/RappPBPK.\nSou T (2025). RappPKPLT: Shiny Application for a PK-Platelet-GDF15 Model. R package version 0.0.0.9000, https://github.com/soutomas/RappPKPLT."
  },
  {
    "objectID": "cv.html#patents",
    "href": "cv.html#patents",
    "title": "Portfolio",
    "section": "Patents",
    "text": "Patents\nPatents granted in 10+ countries: AU, EU, US, CA, CN, MX, ID, ZA, BR, IN\nMichelle McIntosh, David A Morton, Tomás Sou, Livesey Olerile, Richard Prankerd. Method and formulation for inhalation. WO2013016754A1.\n\nAU: 2011374218\n\nEU: 2739268\n\nUS: 11065297\n\nCA: 2879317\n\nCN: ZL2011800739376\n\nID: IDP000048237\n\nMX: 355833\n\nZA: 2014/01526\n\nBR: BR112014002646-7\n\nIN: 391369"
  },
  {
    "objectID": "cv.html#articles",
    "href": "cv.html#articles",
    "title": "Portfolio",
    "section": "Articles",
    "text": "Articles\n\nSoukarieh F, Mashabi A, Richardson W, Oton EV, Romero M, Dubern JF, Robertson SN, Lucanto S, Markham-Lee Z, Sou T, et al. Design, synthesis, and evaluation of new 1 H-benzo[d]imidazole based PqsR inhibitors as adjuvant therapy for Pseudomonas aeruginosa Infections. J Med Chem. 2024;67(2):1008-1023. DOI: https://doi.org/10.1021/acs.jmedchem.3c00973.\nGkoufa A, Sou T, Karaiskos I, Routsi C, Lin YW, Psichogiou M, et al. Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulization of CMS among patients with ventilator-associated pneumonia. Int J Antimicrob Agents. 2022;59(6):106588. DOI: https://doi.org/10.1016/j.ijantimicag.2022.106588.\nSou T, Hansen J, Liepinsh E, Backlund M, Ercan O, Grinberga S, et al. Model-informed drug development for antimicrobials: Translational PK and PK/PD modeling to predict an efficacious human dose for apramycin. Clin Pharmacol Ther. 2021;109(4):1063-1073. DOI: https://doi.org/10.1002/cpt.2104.\nSou T, Bergström CAS. Contemporary formulation development for inhaled pharmaceuticals. J Pharm Sci. 2021;110(1):66-86. DOI: https://doi.org/10.1016/j.xphs.2020.09.006.\nSoukarieh F, Mashabi A, Richardson W, Oton EV, Romero M, Roberston SN, Grossman S, Sou T, et al. Design and Evaluation of New Quinazolin-4(3H)-one Derived PqsR Antagonists as Quorum Sensing Quenchers in Pseudomonas aeruginosa. ACS Infect Dis. 2021;7(9):2666-2685. DOI: https://doi.org/10.1021/acsinfecdis.1c00175.\nSou T, Soukarieh F, Williams P, Stocks MJ, Cámara M, Bergström CAS. Model-informed drug discovery and development in pulmonary delivery: Biopharmaceutical pharmacometric modeling for formulation evaluation of pulmonary suspensions. ACS Omega. 2020;5(40):25733-46. DOI: https://doi.org/10.1021/acsomega.0c03004.\nSou T, Kukavica-Ibrulj I, Levesque RC, Friberg FE and Bergström CAS. Model-informed drug development in pulmonary delivery: Semimechanistic pharmacokinetic-pharmacodynamic modeling for evaluation of treatments against chronic Pseudomonas aeruginosa lung infections. Mol Pharm. 2020;17(5):1458-1469. DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00968.\nBue M, Sou T, Okkels ASL, Hanberg P, Thorsted A, Friberg FE, et al. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy. Int J Infect Dis. 2020;92:133-40. DOI: https://doi.org/10.1016/j.ijid.2020.01.010.\nSoukarieh F, Liu R, Romero M, Roberston SN, Richardson W, Lucanto S, Oton EV, Qudus NR, Mashabi A, Grosmann S, Ali S, Sou T, et al. Hit identification of new potent PqsR antagonists as inhibitors of quorum sensing in planktonic and biofilm grown Pseudomonas aeruginosa. Front Chem. 2020;8(204). DOI: https://doi.org/10.3389/fchem.2020.00204.\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. Model-based drug development in pulmonary delivery: Pharmacokinetic analysis of novel drug candidates for treatment of Pseudomonas aeruginosa lung infection. J Pharm Sci. 2019;108(1):630-640. DOI: https://doi.org/10.1016/j.xphs.2018.09.017.\nSou T, Bergström CAS. Automated assays for thermodynamic (equilibrium) solubility determination. Drug Discov Today Technol. 2018;27:11-9. DOI: https://doi.org/10.1016/j.ddtec.2018.04.004.\nSou T, Forbes RT, Gray J, Prankerd RJ, Kaminskas LM, McIntosh MP, et al. Designing a multi-component spray-dried formulation platform for pulmonary delivery of biopharmaceuticals: The use of polyol, disaccharide, polysaccharide and synthetic polymer to modify solid-state properties for glassy stabilisation. Powder Technology. 2016;287:248-55. DOI: https://doi.org/10.1016/j.powtec.2015.10.008.\nSou T, Morton DAV, Williamson M, Meeusen EN, Kaminskas LM, McIntosh MP. Spray-dried influenza antigen with trehalose and leucine produces an aerosolizable powder vaccine formulation that induces strong systemic and mucosal immunity after pulmonary administration. J Aerosol Med Pulm Drug Deliv. 2015;28(5):361-71. DOI: https://doi.org/10.1089/jamp.2014.1176.\nSou T, McIntosh MP, Kaminskas LM, Prankerd RJ, Morton DAV. Designing a multicomponent spray-dried formulation platform for pulmonary delivery of biomacromolecules: The effect of polymers on the formation of an amorphous matrix for glassy state stabilization of biomacromolecules. Drying Technology. 2013;31(13-14):1451-8. DOI: https://doi.org/10.1080/07373937.2013.788019.\nSou T, Kaminskas LM, Nguyen TH, Carlberg R, McIntosh MP, Morton DAV. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur J Pharm Biopharm. 2013;83(2):234-43. DOI: https://doi.org/10.1016/j.ejpb.2012.10.015.\nSou T, Orlando L, McIntosh MP, Kaminskas LM, Morton DAV. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: A design of experiment approach. Int J Pharm. 2011;421(2):220-9. DOI: https://doi.org/10.1016/j.ijpharm.2011.09.018.\nSou T, Meeusen EN, de Veer M, Morton DAV, Kaminskas LM, McIntosh MP. New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol. 2011;29(4):191-8. DOI: https://doi.org/10.1016/j.tibtech.2010.12.009. (Journal cover)"
  },
  {
    "objectID": "cv.html#presentations",
    "href": "cv.html#presentations",
    "title": "Portfolio",
    "section": "Presentations",
    "text": "Presentations\n\nSou T, Liepins E, Hansen J, Grinberga S, Backlund M, Ercan O, et al. “Translational PK and PKPD modelling of preclinical in-vitro and in-vivo studies to predict the efficacious human dose of apramycin”. ECCMID, Amsterdam, Netherlands. Apr 2019. (Selected for oral presentation with travel grant award)\nSou T. “New generation antimicrobials for the treatment of Pseudomonas aeruginosa”. 8th Symposium on Pharmaceutical Profiling in Drug Discovery and Development, Uppsala University, Uppsala, Sweden. 25 Jan 2018. (Invited speaker)\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. “Quorum sensing inhibitors for pulmonary delivery as a novel treatment strategy against Pseudomonas aeruginosa”. 6th FIP Pharmaceutical Sciences World Congress, Stockholm, Sweden. 21-24 May 2017. (Selected for oral presentation)\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. “Quorum sensing inhibitors for pulmonary delivery as a novel treatment strategy against Pseudomonas aeruginosa”. Northern Pharma Network Meeting, Tartu, Estonia. Jan 2017. (Selected for oral presentation)"
  },
  {
    "objectID": "cv.html#posters",
    "href": "cv.html#posters",
    "title": "Portfolio",
    "section": "Posters",
    "text": "Posters\n\nSou T, Lacroix B, Naik H, Khandelwal A, Coello N. Horseshoe prior as a fast and efficient approach for covariate selection in pharmacometric modelling. PAGE 33 (2025) Abstr 11683 [www.page-meeting.org/?abstract=11683]\nGraham G, Sou T. Continuous-time Markov models: Investigation into the use of Stan and msm for fitting disease progression models for EDSS in multiple sclerosis. PAGE 33 (2025) Abstr 11452 [www.page-meeting.org/?abstract=11452]\nCoello N, Lacroix B, Faller T, Naik H, Sou T, et al. Exposure-response analysis of minzasolmin in Parkinson’s disease using a lean fit for purpose approach to inform decision making. PAGE 33 (2025) Abstr 11519 [www.page-meeting.org/?abstract=11519]\nSou T, Lorenzo S, Sechaud R, Weber HJ. Population PK/PD modelling to evaluate the effect of siremadlin and disease progression on platelet dynamics in haematological malignancies. PAGE 32 (2024) Abstr 10920 [www.page-meeting.org/?abstract=10920]\nSou T, Meille C, Lorenzo S, Sechaud R. Population PK/PD modelling of platelet dynamics for dose selection in patients with haematological malignancies. PAGE 31 (2023) Abstr 10337 [www.page-meeting.org/?abstract=10337]\nSou T, Hansson E, Bergstrand M, Callewaert F, de Passos Sousa R, Sargentini-Maier ML. Caplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura. PAGE 29 (2021) Abstr 9653 [www.page-meeting.org/?abstract=9653]\nSou T, Callewaert F, de Passos Sousa R, Sargentini-Maier ML. PKPD modeling and simulations highlight the importance of the intravenous loading dose and daily dosing regimen with caplacizumab for patients with aTTP. International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, Hosted from Philadelphia, USA. 17-21 Jul 2021.\nSou T, Liepins E, Hansen J, Grinberga S, Backlund M, Ercan O, et al. Translational PK and PKPD modelling of preclinical in-vitro and in-vivo studies to predict the efficacious intravenous human dose of apramycin. ASM/ECSMID Conference on Drug Development, Boston, USA. 3-6 Sep 2019.\nSou T, Liepins E, Hansen J, Grinberga S, Backlund M, Ercan O, et al. Translational PK and PKPD modelling of preclinical in-vitro and in-vivo studies to predict the efficacious human dose of apramycin. PAGE 28 (2019) Abstr 8890 [www.page-meeting.org/?abstract=8890]\nGkoufa A, Karaiskos I, Routsi C, Friberg L, Sou T, Lin YW, et al. Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin following nebulisation of CMS at a dose of 3 MIU and 5 MIU in ICU patients with ventilator-associated pneumonia. ECCMID, Amsterdam, Netherlands. Apr 2019.\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. PK/PD of quorum sensing inhibitors for pulmonary delivery as a novel treatment against Pseudomonas aeruginosa. CRS Annual Meeting, New York, USA. Jul 2018.\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. Pharmacokinetic modelling of a new antimicrobial agent for Pseudomonas aeruginosa lung infection. World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spain. Mar 2018.\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. Quorum sensing inhibitors for pulmonary delivery as a novel treatment against Pseudomonas aeruginosa. Northern Pharma Network Meeting, Odense, Denmark. 29-31 Jan 2018. (Best presentation award with travel grant to CRS NY 2018)\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. A pharmacokinetic model of a new antimicrobial agent after pulmonary delivery for the treatment of chronic Pseudomonas aeruginosa lung infection. American Association of Pharmaceutical Scientists Annual Meeting, San Diego, USA. 12-15 Nov 2017.\nSoukarieh F, Sou T, Iubatti M, Kukavica-Ibrulj I, Oton EV, Halliday N, Bergström CAS, et al. SENBIOTAR: Sensitizing Pseudomonas aeruginosa biofilms to antibiotics and reducing virulence through novel target inhibition. International Conference on Pseudomonas, Liverpool, UK. 2017.\nSou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, et al. Quorum sensing inhibitors for pulmonary delivery as a novel treatment against Pseudomonas aeruginosa. FIP Young Scientist Satellite Conference, Uppsala, Sweden. May 2017.\nSou T, Kaminskas LM, McIntosh MP, Morton DAV. Investigation of the protective effect of L-leucine on particle formation of hygroscopic excipients during spray-drying. Drug Delivery to the Lungs 23, Edinburgh, UK. Dec 2012.\nSou T, Nassta T, Kaminskas LM, McIntosh MP, Prankerd R, Orlando L, et al. Particle engineering of a mannitol-based powder formulation for delivery of biomolecules to the lung. Drug Delivery to the Lungs 22, Edinburgh, UK. Dec 2011.\nSou T, McIntosh MP, Kaminskas LM, Orlando L, Morton DAV. The interaction effect of leucine, glycine and alanine on the performance of a mannitol dry powder formulation. American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, USA. 2010.\nSou T, McIntosh MP, Kaminskas LM, Orlando L, Morton DAV. An investigation on the interaction effect of amino acids on the performance of a mannitol dry powder formulation using a design of experiment approach. Globalisation of Pharmaceutical Education Conference 2010, North Carolina, USA. 2010."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Home",
    "section": "",
    "text": "Tomás Sou\nExplorer. Pharmacist. Researcher. Foodie. Snapper.\nI like travelling and can’t seem to find enough time to see the world. I care about people and want to contribute to the health and well-being of communities. I look into science in the hope of advancing our future with it. I’m grateful for nice cuisines and wish for more opportunities to indulge my taste. I cherish beautiful scenes and give my best shots to capture the moments.\nI am a registered pharmacist in Australia and a research scientist specialising in integrated pharmaceutical R&D. I have over 10 years of combined clinical and R&D experience supporting the development and clinical use of medicines in multinational corporations and consortia. The interest of my work revolves around the synergistic application of data analytics and drug delivery science in predictive pharmacology and quantitative medicine to accelerate the development of new treatments.\nIf you would like to know more about my work, please feel free to contact me and follow for updates."
  }
]